Candel Therapeutics, Inc. (CADL) stock
CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.32−0.08 (-1.48%)
Close on Nov 18, 2026Market cap $407.08MP/E –Yield –
Candel Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Candel Therapeutics's revenue for the twelve months ending Dec 31, 2022 was $125.00K, up 0.0% year over year. For fiscal 2022 it was $125.00K, up 0.0% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $125.00K | 0.0% |
| FY2021 | Dec 31, 2021 | $125.00K | 0.0% |
| FY2020 | Dec 31, 2020 | $125.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2022 | Dec 31, 2022 | $31.00K | 0.0% |
| Q3 FY2022 | Sep 30, 2022 | $31.00K | 0.0% |
| Q2 FY2022 | Jun 30, 2022 | $31.00K | 0.0% |
| Q1 FY2022 | Mar 31, 2022 | $31.00K | 0.0% |
| Q4 FY2021 | Dec 31, 2021 | $31.00K | 0.0% |
| Q3 FY2021 | Sep 30, 2021 | $31.00K | 0.0% |
| Q2 FY2021 | Jun 30, 2021 | $31.00K | 0.0% |
| Q1 FY2021 | Mar 31, 2021 | $31.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $31.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $31.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $31.00K | – |
See a number that looks wrong?